Alogliptin after Acute Coronary Syndrome in Patients with Type 2 Diabetes

B. White, William; P. Cannon, Christopher; Heller, Simon; E. Nissen, Steven; M. Bergenstal, Richard; L. Bakris, George; T. Perez, Alfonso; Fleck, P.; R. Mehta, Cyrus; Kupfer, Stuart; Wilson, Craig; C. Cushman, William; Zannad, Faı̈ez

doi:10.1056/nejmoa1305889

Public

Alogliptin after Acute Coronary Syndrome in Patients with Type 2 Diabetes

Published in New England Journal of Medicine • Sep 2, 2013

Authors:

William B. White

Christopher P. Cannon

Simon Heller

Abstract

BACKGROUND: To assess potentially elevated cardiovascular risk related to new antihyperglycemic drugs in patients with type 2 diabetes, regulatory agencies require a comprehensive evaluation of the cardiovascular safety profile of new antidiabetic therapies. We assessed cardiovascular outcomes with ...

Subject

Alogliptin

Acute coronary syndrome

Type 2 diabetes

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!